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MAGNITUDE OF THE PROBLEM
Hypertension affects about 25% of the adult population in
the United States, or about 50 million people (1,2). Over
the past 30 years great strides have been made in improving
awareness, treatment and control of high blood pressure (1).
These advances in blood pressure control have contributed
to dramatic declines in morbidity and mortality attributed to
hypertension. Over this period of time, death rates from
stroke have fallen by about 60%, and death rates from
coronary heart disease have fallen by over 50% (3,4).
Unfortunately, recent evidence suggests that in the last few
years the improvements in awareness, treatment and control
of high blood pressure have leveled off and only about a
quarter of adults with hypertension are currently controlled
(Table 1) (5). In a parallel manner, the national declines in
stroke and heart disease mortality also have flattened (3,4).
DEFINING HYPERTENSION AND HYPERTENSION
CONTROL
Hypertension is defined as a systolic blood pressure
$140 mm Hg or a diastolic pressure $90 mm Hg or the
current use of medication for treatment of high blood
pressure (5). The classification of blood pressure stages is
summarized in Table 2. Hypertension control is defined as
achieving and maintaining blood pressure levels below
140 mm Hg systolic and 90 mm Hg diastolic. Even lower
levels are recommended for patients with heart failure,
diabetes and renal disease (5).
CAUSAL ROLE OF HYPERTENSION IN
CARDIOVASCULAR DISEASE
Observational data have long indicated that cardiovascular
disease risk increases as levels of blood pressure advance
(6–9). The association of hypertension with risk is especially
notable for stroke (6), heart failure (8) and endstage renal
disease (9). Although clinical practice and guidelines on
hypertension treatment once focused primarily on elevation
of diastolic blood pressure, the risks associated with systolic
hypertension have now been well established. This is espe-
cially important in older persons in whom isolated systolic
hypertension is the most common form of hypertension
(10).
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Table 1. Trends in Awareness, Treatment and Control of
Hypertension* (5)
NHANES II
1976–80
NHANES III
(Phase 1)
1988–91
NHANES III
(Phase 2)
1991–94
Awareness 51% 73% 68%
Treatment 31% 55% 54%
Control† 10% 29% 27%
*Adults age 18 to 74 years with SBP $140 mm Hg or DBP $90 mm Hg or taking
antihypertensive medication. †SBP ,140 mm Hg and DBP ,90 mm Hg.
DBP 5 diastolic blood pressure, SBP 5 systolic blood pressure.
Table 2. Classification of Blood Pressure Stages* (5)
Category
Systolic BP
(mm Hg)
Diastolic BP
(mm Hg)
Optimal ,120 and ,80
Normal ,130 and ,85
High-normal 130–139 or 85–89
Stage 1 hypertension 140–159 or 90–99
Stage 2 hypertension 160–179 or 100–109
Stage 3 hypertension $180 or $110
*When systolic and diastolic pressures fall into two different categories, the higher
stage should be used for classification.
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BENEFITS OF HYPERTENSION CONTROL
The causal role of blood pressure in the pathogenesis of
cardiovascular disease is confirmed by the results of clinical
trials documenting reductions in risk for stroke, heart failure
and myocardial infarction in hypertensive patients whose
blood pressure is lowered (11,12). Meta-analyses of clinical
trials have indicated reductions in risk for stroke by more
than 40% (11) and heart failure by about 50% (13,14).
Clinical trials of blood pressure treatment in patients with
isolated systolic hypertension also have shown dramatic
reductions in cardiovascular risk in response to treatment
(15,16).
WHAT’S NEW IN JNC VI
The Sixth Report of the Joint National Committee on
Prevention, Detection, Evaluation and Treatment of High
Blood Pressure (JNC VI) (5) is an update of the previous
guideline (JNC V) (17) and contains important new infor-
mation for clinicians. JNC VI was developed using
evidence-based medicine and expert consensus to make
recommendations to clinicians. It provides a contemporary
approach to hypertension prevention and control. New
information incorporates data from phase 2 of the third
National Health and Nutrition Examination Survey, up-
dated information on the year 2000 objectives for the
nation, a discussion of new pharmacologic therapies (in-
cluding combination drugs), the role of managed care in the
treatment of high blood pressure and information from
recently completed randomized controlled trials on hyper-
tension prevention and treatment. In addition, the report
contains a guide to help clinicians individualize treatment by
stratifying patients’ risks. A revised treatment algorithm, as
well as detailed and updated strategies for special popula-
tions and situations, is provided to guide clinicians.
THE ROLE OF CARDIOLOGISTS IN MANAGING
HYPERTENSION
The new recommendations for hypertension treatment are
based on not only the level of blood pressure but also on the
level of other risk factors (Table 3). Hypertensive patients
with heart disease or target organ damage, who are often in
the care of a cardiologist, fall into a high risk category (Risk
Group C). Because of their high risk, hypertensive patients
with heart disease have a lower treatment threshold and a
lower target blood pressure. These are patients in whom
blood pressure control is crucial for ensuring cardiovascular
wellness. Because hypertensive target organ damage is
preventable and predisposes to the development of clinical
cardiovascular disease, early and aggressive treatment of
hypertension remains an important public health challenge
that must be addressed by cardiologists.
A CALL TO ACTION
The risks associated with high blood pressure are clear. The
evidence that hypertension treatment can reduce risk for
cardiovascular disease complications is irrefutable. Never-
theless, rates of awareness, treatment and control of high
blood pressure remain unacceptably low (1). Cardiologists
provide primary and consultative care to the highest risk
hypertensive patients, who benefit most from blood
pressure control. JNC VI is an invaluable desktop re-
source that can assist cardiologists in achieving far higher
rates of blood pressure control in their patients with high
blood pressure.
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